India
Big pharma´s patent wars in India
The Indian Supreme court has rejected a key patent of Novartis for their cancer drug Glivec. The verdict adds to a series of strikes against multinational pharmaceutical companies to gain patent rights in India, potentially one of the biggest pharmaceutical markets in the world. Continue reading
Indian government forces Bayer to accept generic Nexavar competition – FiercePharma
India has invoked its compulsory licensing rules for the first time to make and sell a version of Bayer's cancer drug Nexavar despite the fact that Nexavar is still on patent.
We think this is quite a significant development. What does it mean for ROI of big pharma companies R&D ? What does it mean for IP integrity for doing business in India ? Continue reading